SCHEMBL2454952

SCHEMBL2454952

COC(=O)CCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
HTT P42858 2/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NOTUM Q6P988 1/20 0.39
KDM4E B2RXH2 1/20 0.38
BRD4 O60885 1/20 0.38
KAT2B Q92831 2/20 0.36
MEN1 O00255 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PSMB8 P28062 1/20 0.34
PSMB5 P28074 1/20 0.34
CA12 O43570 1/20 0.34
CA14 Q9ULX7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264567 0.93 TSHR (0.48) TSHRALDH1A1LMNAKMT2AHTT
SCHEMBL14141438 0.93 TSHR (0.54) TSHRALDH1A1LMNAKMT2AHTT
Ether SCHEMBL7956358 0.92 TSHR (0.42) TSHRALDH1A1LMNAKMT2AHTT
SCHEMBL905407 0.91 TSHR (0.47) TSHRALDH1A1LMNAKMT2AHTT
SCHEMBL19463301 0.91 TSHR (0.47) TSHRALDH1A1LMNAKMT2AHTT
SCHEMBL29044559 0.91 TSHR (0.47) TSHRALDH1A1LMNAKMT2AHTT
SCHEMBL19696384 0.90 TSHR (0.41) TSHRALDH1A1LMNAKMT2AHTT
SCHEMBL43576 0.90 PSMB8 (0.35) TSHRLMNAKMT2AHPGDSMN1; SMN2
SCHEMBL31522720 0.88 PSMB8 (0.34) LMNAKMT2AHTTHPGDSMN1; SMN2
SCHEMBL13183261 0.86 BRD4 (0.39) TSHRALDH1A1KMT2AHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116916965-A Bioactive material conjugates with conjugated biotin moieties, fatty acid moieties, or combinations thereof D&D制药技术股份有限公司 2023-10-20 CN claimed
EP-0396709-A4 HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME 1991-05-22 EP claimed
EP-0396709-A1 HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1990-11-14 EP claimed
EP-0367514-A2 Human leukocyte elastase inhibitors and methods for producing and using same UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1990-05-09 EP claimed
WO-1990004409-A1 HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1990-05-03 WO claimed
EP-3581195-B1 ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF JANSSEN PHARMACEUTICA NV (BE) 2025-10-01 EP disclosed
EP-3492473-B1 HAPTENS OF OLANZAPINE JANSSEN PHARMACEUTICA NV (BE) 2025-07-30 EP disclosed
WO-2024220546-A2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AND METHODS OF USE AND SYNTHETIC PROCESSES AND INTERMEDIATES PEAK BIO, INC. (US) 2024-10-24 WO disclosed
CN-116940384-A Oral formulations having bioactive material conjugates coupled to biotin moieties, fatty acid moieties, or combinations thereof D&D制药技术股份有限公司 2023-10-24 CN disclosed
CN-116916965-A Bioactive material conjugates with conjugated biotin moieties, fatty acid moieties, or combinations thereof D&D制药技术股份有限公司 2023-10-20 CN disclosed
US-20230321267-A1 Method And Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed
US-11759526-B2 Method and molecules MEDIMMUNE, LLC (US) 2023-09-19 US disclosed
US-20020032306-A1 CYCLOPEPTIDE DERIVATIVES BIOMET DEUTSCHLAND GMBH (DE) 2002-03-14 US disclosed
US-6316669-B1 OPHTHALMOLOGY ALCON MANUFACTURING, LTD. 2001-11-13 US disclosed
US-5922319-A REDUCING SCARING IN EYES UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1999-07-13 US disclosed
EP-0396709-A4 HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME 1991-05-22 EP disclosed
US-5008245-A Antiinflammatory agents UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1991-04-16 US disclosed
EP-0396709-A1 HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1990-11-14 EP disclosed
EP-0367514-A2 Human leukocyte elastase inhibitors and methods for producing and using same UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1990-05-09 EP disclosed
WO-1990004409-A1 HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1990-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321267-A1 Method And Molecules PAICS, EPCAM, SQLE TSHR 1084/4885ALDH1A1 27/4885LMNA 1762/4885
US-11759526-B2 Method and molecules PAICS, EPCAM, SQLE TSHR 1084/4885ALDH1A1 27/4885LMNA 1762/4885
US-20020032306-A1 CYCLOPEPTIDE DERIVATIVES CORO1C, CYCS, CORO1A TSHR 1623/4885ALDH1A1 4557/4885LMNA 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.